

Pharma in brief - Canada

Federal Court strikes application under s. 6(5)(b) for lack of evidence

Case:	<i>Valeant Canada LP v Apotex Inc</i> , 2016 FC 1359 (Court File No. T-953-16)
Drug:	GLUMETZA [®] (metformin)
Nature of case:	Motion to dismiss prohibition application pursuant to section 6(5)(b) of the <i>Patented Medicines (Notice of Compliance) Regulations (Regulations)</i>
Successful party:	Apotex Inc
Date of decision:	December 8, 2016

Summary

Apotex successfully brought a motion to strike Valeant's application under section 6(5)(b) of the *Regulations* on the grounds that the application is an abuse of process or is otherwise scandalous and vexatious. In response, Valeant did not file any evidence and argued that it has no burden to prove anything on the motion as it has a right to a hearing on the merits. The court held that Valeant had no arguable case, and therefore Valeant's application is bereft of any chance of success and must be struck.

Background

Valeant markets metformin tablets under the name GLUMETZA[®] for the treatment of type 2 diabetes. Apotex sought approval to market its generic 1000 mg metformin tablets and was required to address Valeant's patent. The patent relates to a pharmaceutical composition with a controlled-released coating prepared by a specific process.

In support of its motion to strike, Apotex filed an affidavit from an expert who reviewed Valeant's patent and details of Apotex's formulation as described in its regulatory submission. The expert opined that Apotex's tablets will not infringe Valeant's patent, as the tablets will not contain or be made according to the claims of the patent and will not comprise a coating or a pharmaceutical dosage that operates in the same manner as the dosage forms and coatings of the patent.

Lack of evidence

In what the court described as a "calculated strategic decision," Valeant did not file any evidence in this motion nor in the application. The court also noted that Valeant's notice of application simply alleged that Apotex's allegations of non-infringement were not justified and did not provide the grounds upon which it claims a prohibition order.

As the premise of the *Regulations* is to prevent infringement, Apotex argued that, in the absence of any evidence of infringement, Valeant's application is an abuse of process.

Valeant contended that it has a right to a hearing on the merits, but no burden to prove anything or obligation to respond to Apotex's case on the motion to strike. Valeant also argued Apotex has the burden of demonstrating there is no possible witness anywhere that might support Valeant's case and that by bringing such a motion Apotex will obtain two opportunities to make its case.

Prothonotary Aalto rejected Valeant's arguments and held that it is not sufficient for a party to commence an application without any grounds set out in the application to support its case. Further, the burden on this motion requires Apotex to demonstrate that Valeant's application is bereft of any chance of success, which it has done by demonstrating that its tablets do not infringe the patent. Prothonotary Aalto therefore held that Valeant failed to demonstrate that its application was not bereft of any chance of success.

The right to a hearing is subject to the merits of the application

The court acknowledged Valeant is entitled to a hearing on the merits provided that the application as a whole is not bereft of any chance of success. The right to a hearing is a qualified right that cannot be given when there is no merit to the application. In this case, the court concluded that as there was no arguable case on the merits of Valeant's application, the application is bereft of any chance of success and must be struck.

Link:

Valeant Canada LP v Apotex Inc, [2016 FC 1359](#)

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.